| NCT ID | NCT06658496 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Patent Ductus Arteriosus |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-12-19 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2024-12-19 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney injury. Researchers will do this by looking at ultrasound images of the heart, analyzing substances in the urine, and evaluating oxygen levels in the kidneys.
Eligibility Criteria
Inclusion Criteria: * Delivered at \<32 weeks' gestation * ≤72 hours of age * Inpatient at Meriter Hospital, Inc. NICU * At least one parent/guardian is able to provide parental permission in English or Spanish Exclusion Criteria: * Major congenital anomalies of kidney * Attending physician's discretion to not place NIRS sensors due to clinical concerns * In the PI or Co-I's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life * Birth parent aged \<18
Contact & Investigator
Matthew Harer, MD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT06658496 clinical trial?
This trial is open to participants of all sexes, aged 1 Minute or older, up to 7 Days, studying Patent Ductus Arteriosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06658496 currently recruiting?
Yes, NCT06658496 is actively recruiting participants. Contact the research team at pcondit@wisc.edu for enrollment information.
Where is the NCT06658496 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06658496 clinical trial?
NCT06658496 is sponsored by University of Wisconsin, Madison. The principal investigator is Matthew Harer, MD at University of Wisconsin, Madison. The trial plans to enroll 45 participants.